WALTHAM, Mass.--(BUSINESS WIRE)--At the American Association for Cancer Research 2013 Annual Meeting (Booths 1513, 1424) PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, will showcase a full suite of solutions designed to accelerate cancer research. The Company will introduce an expanded portfolio of assays, informatics and application protocols used in next generation sequencing (NGS) and molecular diagnostics, all designed to advance personalized medicine-based cancer research.
“PerkinElmer is committed to advancing the improvement of human health through better diagnosis, treatment and prevention of cancer,” said Kevin Hrusovsky, president, Life Sciences & Technology, PerkinElmer. “At this year’s AACR, we are excited to unveil some of our most innovative cancer research solutions that are designed to accelerate genomic analysis, advance in-vivo tumor visualization, and identify biomarkers that will accurately predict safety and efficacy of biologic treatments. Advancements in next generation sequencing, pathology and informatics are revolutionizing the way our customers create new solutions to diagnose and treat cancer.”
At the show, PerkinElmer will launch a new genomic DNA assay for the analysis of DNA degradation in cancer research studies. The genomic DNA assay enables rapid automation of quality testing of DNA and RNA samples and complements a suite of research tools for the LabChip® GX Nucleic Acid Separation System. Utilizing a proprietary Genomic Quality Score (GQS) algorithm that provides a reproducible, digital quality metric, the assay is designed to ensure that only DNA samples of the highest quality are evaluated to accelerate the NGS workflow.
PerkinElmer will also unveil key validated protocols for NGS applications used in cancer research using the Sciclone® NGS liquid handling workstation. Automating the next generation sequencing process helps to avoid sample tracking errors while reducing sample-to-sample variability and dramatically accelerates throughput for downstream sequencing. The new Sciclone automation protocols include:
The Sciclone automated workstation also accommodates high-throughput sample preparation for chemagen FFPE DNA extractions used in cancer research studies.
PerkinElmer will feature several poster presentations at AACR 2013:
PerkinElmer assists researchers, clinicians and physicians to help combat cancer in a variety of meaningful ways, including facilitating the detection of environmental contaminants to help people avoid cancer, developing technologies used for cancer research and providing digital flat panel detector components for more precise imaging for diagnosing and monitoring cancer.
Continue the conversation at AACR online by following on twitter at @PKILifeScience with the tag #AACR.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Edelman (on behalf of PerkinElmer)
Paul Barren, 404-460-9679